Brief: Kancera: Preclinical Projects ROR1 And PFKFB3 Are Discontinued

Novakand Pharma AB

17/11/2023 07:39

Nov 17 (Reuters) - Kancera AB  KANC.ST :
    * PROVIDES AN OPERATIONAL UPDATE REGARDING ITS FRACTALKINE
BLOCKERS KAN567 AND KAND145, BOTH IN CLINICAL STAGE
    * REPORTS THAT PRECLINICAL PROJECTS ROR1 AND PFKFB3 ARE
DISCONTINUED AND FOCUS ON CLINICAL DEVELOPMENT WITHIN
FRACTALKINE PROGRAM IS FURTHER STRENGHTENED

Source text for Eikon:  ID:nMFNbRXqql 
Further company coverage:  KANC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))